oxazoles has been researched along with Migraine Disorders in 80 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.25) | 18.7374 |
| 1990's | 66 (82.50) | 18.2507 |
| 2000's | 12 (15.00) | 29.6817 |
| 2010's | 1 (1.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Huniti, N; Birmingham, B; Li, J; Lillieborg, S; Xu, H; Zhou, D; Zhou, W | 1 |
| CANELLAS RODRIGUEZ, R | 1 |
| Cox, RC; Ferrari, MD; Jones, D; Klein, KB; Visser, WH | 1 |
| Ferrari, MD | 3 |
| Earl, NL | 1 |
| Martin, GR | 2 |
| Geraud, GE | 1 |
| Dowson, A | 1 |
| Edmeads, JG | 1 |
| Bendtsen, L; Daugaard, D; Dixon, R; Gibbens, M; Langemark, M; Lassen, LH; Olesen, J; Thomsen, LL | 1 |
| Churchus, R; On, N; Phillips, S; Posner, J; Rolan, P; Seaber, E | 1 |
| Goadsby, PJ; Hoskin, KL | 2 |
| Goadsby, PJ; Olesen, J | 1 |
| Zagami, AS | 1 |
| Dowson, AJ | 1 |
| Dixon, R; Gibbens, M; Gillotin, C; Peck, RW; Posner, J | 1 |
| Chittick, G; Dixon, RM; Gibbens, M; Leavens, WJ; Liptrot, J; On, N; Pack, RW; Posner, J; Rolan, PE; Seaber, E | 1 |
| Goadsby, PJ | 3 |
| Schoenen, J | 1 |
| Dahlöf, C | 1 |
| Cutrer, FM; Moskowitz, MA | 1 |
| Cady, RK; Earl, NL; Klapper, JA; Ramadan, NM; Saper, JR; Solomon, GD | 1 |
| Adelman, JU; Earl, NL; Elkind, AH; Kudrow, DB; Mathew, NT; Ramadan, NM; Rapoport, AM | 1 |
| Mathew, N | 1 |
| Dixon, R; Warrander, A | 1 |
| Rolan, P | 1 |
| Sawyer, J; Schoenen, J | 1 |
| Lipton, RB; Stewart, WF | 1 |
| Bagnis, C; Deray, G; Gillotin, C; Mamet, JP; Peck, RW | 1 |
| Afra, J; Proietti-Cecchini, A; Schoenen, J | 1 |
| Layton, G; Peck, RW; Posner, J; Ridout, G; Seaber, EJ | 1 |
| Arnold, G; Back, T; Dirnagl, U; Dreier, J; Einhäupl, KM; Gold, L; Reuter, U | 1 |
| Guanci, R; Lilley, LL | 1 |
| Pascual, J | 1 |
| Leira, R; Noya, M | 1 |
| Morales Asín, F | 1 |
| Cambridge, D; MacLennan, SJ; Marston, C; Martin, GR; Whiting, MV | 1 |
| Cumberbatch, MJ; Hargreaves, RJ; Hill, RG | 1 |
| Monseu, G; Sternon, J | 1 |
| Diener, HC; Fritsche, G; Kazarawa, Z; Limmroth, V | 1 |
| Beer, MS; Guiblin, AR; Heald, A; Hunt, PA; Jelley, RA; Matassa, VG; Reeve, AJ; Sohal, B; Stanton, JA; Sternfeld, F; Street, LJ; Watt, AP | 1 |
| Cummings, L; Dane, A; Dixon, R; Hughes, AM; Kemp, J; Yates, RA | 1 |
| Dixon, R; Engleman, K; Kemp, J; Ruckle, JL | 1 |
| Deleu, D; Hanssens, Y | 2 |
| Gunasekara, NS; Hills, C; Spencer, CM | 1 |
| Diener, HC; Limmroth, V | 1 |
| Buzzi, MG | 1 |
| Le Jeunne, C | 1 |
| Dixon, R | 1 |
| Diener, HC; Dowson, AJ; Ferrari, M; Nappi, G; Tfelt-Hansen, P | 1 |
| Amelin, AV; Korenko, LA; Skoromets, AA | 1 |
| Bartlett, MG; Stewart, JT; Vishwanathan, K | 1 |
| Bomhof, MA; Donnan, GA; Dowson, AJ; Elkind, A; Fletcher, PE; Meloche, J; Millson, DS; Tepper, SJ | 1 |
| Edvinsson, L; Geraud, G; Korczyn, A; Mauskop, A; Pfaffenrath, V; Tuchman, M | 1 |
| Farkkila, M; Hering-Hanit, R; Mauskop, A; Rapoport, A; Warner, J | 1 |
| Logemann, CD; Rankin, LM | 1 |
| Nater, B; Regli, F | 1 |
| Peacock, JH; Vijayan, N | 1 |
| Chitra, R; Dennish, G; Gallagher, RM; Spierings, EL | 1 |
| Duckmanton, L | 1 |
| Diener, HC; Geraud, G; Olesen, J; Pfaffenrath, V; Sweet, R; Tfelt-Hansen, P; Zupping, R | 1 |
| Chernyshev, O; Gentry, P; Kailasam, J; Mathew, NT | 1 |
| de Tommaso, M; Guido, M; Libro, G; Puca, F; Sciruicchio, V | 1 |
| Bartleson, JD | 1 |
| Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P | 1 |
20 review(s) available for oxazoles and Migraine Disorders
| Article | Year |
|---|---|
The clinical effectiveness of 311C90 in the acute treatment of migraine.
Topics: Double-Blind Method; Humans; Migraine Disorders; Multicenter Studies as Topic; Oxazoles; Oxazolidinones; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Time Factors; Treatment Outcome; Tryptamines | 1996 |
Clinical safety of 311C90: aggregated data from patients and volunteers to date.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Reference Values; Serotonin Receptor Agonists; Tryptamines | 1996 |
Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action.
Topics: Administration, Oral; Biological Availability; Cerebrovascular Circulation; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Trigeminal Nerve; Tryptamines | 1996 |
Emerging preclinical and clinical profile of 311C90: a poster review and discussion.
Topics: Animals; Central Nervous System; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Quality of Life; Serotonin Receptor Agonists; Tryptamines | 1996 |
Increasing the options for effective migraine management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Ergotamine; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Quality of Life; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1997 |
311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
Topics: Headache; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1997 |
Zolmitriptan. Introduction.
Topics: Drug Interactions; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines | 1997 |
Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Topics: Administration, Oral; Animals; Biological Availability; Drug Evaluation, Preclinical; Hemodynamics; Injections, Intravenous; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Topics: Acetaminophen; Adolescent; Adult; Drug Interactions; Drug Therapy, Combination; Ergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Tryptamines | 1997 |
Clinical applications of zolmitriptan (Zomig, 311C90).
Topics: Acute Disease; Disabled Persons; Dose-Response Relationship, Drug; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Tryptamines | 1997 |
[Mechanism of action of zolmitriptan].
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1998 |
[Clinical efficacy of zolmitriptan in migraine].
Topics: Adolescent; Adult; Aged; Humans; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1998 |
[Safety profile of 311C90 (zolmitriptan)].
Topics: Dose-Response Relationship, Drug; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1998 |
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Design; Drug Interactions; Humans; Inactivation, Metabolic; Indoles; Meninges; Migraine Disorders; Molecular Structure; Nociceptors; Oxazoles; Oxazolidinones; Piperidines; Propranolol; Pyrrolidines; Randomized Controlled Trials as Topic; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Recurrence; Serotonin Receptor Agonists; Structure-Activity Relationship; Sumatriptan; Treatment Outcome; Triazoles; Tryptamines; Vasoconstrictor Agents | 1999 |
Zolmitriptan: a review of its use in migraine.
Topics: Age Factors; Clinical Trials as Topic; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1999 |
Acute management of migraine: triptans and beyond.
Topics: Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1999 |
[Zolmitriptan].
Topics: Drug Costs; Drug Interactions; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Patient Selection; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines | 1999 |
The scientific basis of medication choice in symptomatic migraine treatment.
Topics: Acute Disease; Choice Behavior; Dose-Response Relationship, Drug; Humans; Indoles; Migraine Disorders; Models, Biological; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Severity of Illness Index; Sumatriptan; Triazoles; Tryptamines | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic; Dihydroergotamine; Half-Life; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines | 2000 |
Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Topics: Acute Disease; Carbazoles; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Pyrrolidines; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Triazoles; Tryptamines | 2000 |
25 trial(s) available for oxazoles and Migraine Disorders
| Article | Year |
|---|---|
311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
Topics: Administration, Oral; Adolescent; Adult; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Pain Measurement; Placebos; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1996 |
Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Child; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Time Factors; Treatment Outcome; Tryptamines | 1996 |
Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines; United Kingdom | 1996 |
The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
Topics: Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Placebos; Reference Values; Serotonin Receptor Agonists; Tryptamines | 1996 |
311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Research Design; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1997 |
The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Topics: Administration, Oral; Adult; Analysis of Variance; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
[Zolmitriptan: new perspectives in migraine therapy. Satellite symposium of the 11th Migraine Trust International Symposium, London, 10 September 1996].
Topics: Blood-Brain Barrier; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Sumatriptan; Tryptamines | 1997 |
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Topics: Absorption; Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cross-Over Studies; Feces; Female; Half-Life; Humans; Indoleacetic Acids; Infusions, Intravenous; Male; Mass Spectrometry; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Sex Factors; Tryptamines | 1997 |
Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Tryptamines | 1997 |
Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Female; Humans; Menstruation; Middle Aged; Migraine Disorders; Nausea; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Tryptamines | 1997 |
No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Topics: Adult; Aged; Area Under Curve; Blood Pressure; Electrocardiography; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Renal Dialysis; Serotonin Receptor Agonists; Tryptamines | 1997 |
Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
Topics: Adult; Cerebral Cortex; Dose-Response Relationship, Drug; Double-Blind Method; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Synaptic Transmission; Tryptamines | 1997 |
The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
Topics: Acetaminophen; Adult; Blood Pressure; Drug Interactions; Female; Humans; Male; Metoclopramide; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Tryptamines | 1998 |
Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine.
Topics: Acoustic Stimulation; Adult; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Reference Values; Serotonin Receptor Agonists; Tryptamines | 1999 |
A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
Topics: Adolescent; Adult; Aged; Aging; Area Under Curve; Biotransformation; Child; Female; Half-Life; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1999 |
Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.
Topics: Double-Blind Method; Ethics, Medical; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Placebos; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Tryptamines | 1999 |
A long-term study to maximise migraine relief with zolmitriptan.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Tablets; Time Factors; Tryptamines | 1999 |
Zolmitriptan provides consistent migraine relief when used in the long-term.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1999 |
Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1999 |
[Oral zolmitriptan (Zomig) in the treatment of migraine crisis].
Topics: Administration, Oral; Adolescent; Adult; Humans; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 2000 |
A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Patient Satisfaction; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Treatment Outcome; Tryptamines | 2000 |
Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Research Design; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Tryptamines | 2000 |
Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial.
Topics: Administration, Oral; Cross-Over Studies; Drug Resistance; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Retreatment; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 2000 |
35 other study(ies) available for oxazoles and Migraine Disorders
| Article | Year |
|---|---|
Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Body Weight; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Migraine Disorders; Models, Biological; Oxazoles; Oxazolidinones; Serotonin 5-HT1 Receptor Agonists; Tryptamines; Young Adult | 2017 |
[Clinical study of mephenoxalone (Moderamin) in various syndromes of psychogenic etiology and psychiatric treatments].
Topics: Electroconvulsive Therapy; Gastroenterology; Gynecology; Humans; Mental Disorders; Migraine Disorders; Oxazoles; Psychopharmacology; Psychotherapy; Syndrome | 1960 |
Extending therapeutic options? Prospects for the future.
Topics: Cerebrovascular Circulation; Forecasting; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Trigeminal Nerve; Tryptamines | 1996 |
311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1996 |
Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?
Topics: Animals; Brain Stem; Cats; Cranial Sinuses; Dose-Response Relationship, Drug; Electric Stimulation; Electrophysiology; Evoked Potentials; Injections, Intravenous; Migraine Disorders; Neural Inhibition; Neurons; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Trigeminal Caudal Nucleus; Tryptamines | 1996 |
311C90: patient profiles and typical case histories of migraine management.
Topics: Adult; Female; Humans; Male; Menstruation; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Time Factors; Tryptamines | 1997 |
Is a central action of acute antimigraine drugs essential?
Topics: Analgesics; Animals; Brain; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1997 |
Measuring central action of acute antimigraine drugs in humans.
Topics: Analgesics; Brain; Contingent Negative Variation; Electroencephalography; Evoked Potentials, Auditory; Evoked Potentials, Visual; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
Would any acute treatment for migraine demonstrate recurrence?
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Tryptamines | 1997 |
Attacking migraine headache from beginning to end.
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1997 |
The clinical pharmacokinetics of zolmitriptan.
Topics: Absorption; Adult; Case-Control Studies; Female; Humans; Liver Diseases; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tissue Distribution; Tryptamines | 1997 |
Zolmitriptan receives migraine indication.
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1998 |
Oral migraine treatment approved.
Topics: Administration, Oral; Contraindications; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Rabies Vaccines; Serotonin Receptor Agonists; Tryptamines; United States; United States Food and Drug Administration | 1998 |
A triptan too far?
Topics: Acute Disease; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1998 |
Zolmitriptan for migraine.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Tryptamines | 1998 |
Cortical spreading depression-associated hyperemia in rats: involvement of serotonin.
Topics: Animals; Cerebrovascular Circulation; Cortical Spreading Depression; Hyperemia; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Ritanserin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Tryptamines | 1998 |
Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Topics: Animals; Cats; Cerebrovascular Circulation; Cranial Sinuses; Electric Stimulation; Gene Expression Regulation; Genes, fos; Migraine Disorders; Neurons, Afferent; Nociceptors; Oxazoles; Oxazolidinones; Pain; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan; Synaptic Transmission; Trigeminal Caudal Nucleus; Trigeminal Nerve; Trigeminal Nucleus, Spinal; Tryptamines; Vasoconstrictor Agents | 1998 |
It never hurts to check. Taking the time to read a label benefited this migraine sufferer.
Topics: Adult; Contraindications; Drug Labeling; Female; Humans; Medication Errors; Migraine Disorders; Oxazoles; Oxazolidinones; Patient Education as Topic; Reading; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1998 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Dihydroergotamine; Drug Interactions; Ergotamine; Humans; Indoles; Methysergide; Migraine Disorders; Naproxen; Oxazoles; Oxazolidinones; Piperidines; Propranolol; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Timolol; Triazoles; Tryptamines; Valproic Acid; Vasoconstrictor Agents | 1998 |
Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
Topics: Animals; Arteriovenous Anastomosis; Blood Flow Velocity; Carotid Arteries; Cats; Cerebral Cortex; Disease Models, Animal; Dogs; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1998 |
The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Analgesics; Animals; Electric Stimulation; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Receptor Agonists; Trigeminal Caudal Nucleus; Tryptamines | 1998 |
[Zolmitriptan].
Topics: Chemistry, Pharmaceutical; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1998 |
Headache after frequent use of serotonin agonists zolmitriptan and naratriptan.
Topics: Adult; Female; Headache; Humans; Indoles; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Tryptamines | 1999 |
Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Humans; Indoles; Migraine Disorders; Models, Molecular; Oxazoles; Pyrrolidines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Recombinant Proteins; Serotonin Receptor Agonists; Structure-Activity Relationship | 1999 |
Zolmitriptan.
Topics: Drug Interactions; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1999 |
Efficacy of 5HT in migraine.
Topics: Action Potentials; Animals; Cats; Cranial Sinuses; Electric Stimulation; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Tryptamines; Vasoconstrictor Agents | 1999 |
Measuring event-related potentials.
Topics: Adult; Arousal; Contingent Negative Variation; Dexfenfluramine; Event-Related Potentials, P300; Evoked Potentials, Auditory, Brain Stem; Humans; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Tryptamines | 1999 |
[Differentiated therapy of migraine attack].
Topics: Adult; Analgesics; Antiemetics; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Severity of Illness Index; Treatment Outcome; Tryptamines | 1999 |
Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Bufotenin; Chromatography, High Pressure Liquid; Humans; Indoles; Mass Spectrometry; Migraine Disorders; Molecular Structure; Oxazoles; Oxazolidinones; Piperidines; Sensitivity and Specificity; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 2000 |
Spinal cord infarction during use of zolmitriptan: a case report.
Topics: Female; Humans; Infarction; Menstruation; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Spinal Cord; Tryptamines | 2000 |
Drug information incorrect.
Topics: Canada; Contraindications; Drug Interactions; France; Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Propranolol; Serotonin Receptor Agonists; Tryptamines; Vasodilator Agents | 2000 |
Zolmitriptan: new product. Similar to sumatriptan.
Topics: Clinical Trials as Topic; Drug Interactions; Humans; Migraine Disorders; Oxazoles; Placebos; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome | 1999 |
Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans.
Topics: Adolescent; Adult; Blinking; Female; Humans; Male; Middle Aged; Migraine Disorders; Oxazoles; Oxazolidinones; Serotonin Receptor Agonists; Sumatriptan; Trigeminal Ganglion; Tryptamines; Vasoconstrictor Agents | 2000 |
Triptans to the rescue: effective therapy for migraine headaches in the workplace.
Topics: Absenteeism; Adult; Cost-Benefit Analysis; Efficiency; Female; Humans; Indoles; Injections, Subcutaneous; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Randomized Controlled Trials as Topic; Self Administration; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Triazoles; Tryptamines; Workplace | 2000 |
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Brain; Capillary Permeability; Cattle; CHO Cells; Cricetinae; Ear; Electric Stimulation; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Male; Migraine Disorders; Models, Molecular; Oxazoles; Rabbits; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Regional Blood Flow; Serotonin Receptor Agonists; Serum Albumin, Bovine; Structure-Activity Relationship; Trigeminal Ganglion; Vasoconstrictor Agents | 2001 |